Event Panel Schedule


TBA
Gary Nach­man from BMO to dis­cuss Sol-Gel
Webcast
Ed0337a7013d5ac5f35b0a0e3ba53332_d4d0c34fee6ff2c2bd0f23aad556e229_120_120
Sol-Gel Technologies Ltd.
Alon Seri-Levy, PhD, CEO/Co-Founder / Sol-Gel Technologies Ltd.
Dr. Alon Seri-Levy co-founded Sol-Gel and has served as our chief executive officer since our inception in 1997 and as a member of our board of directors until 2014. Prior to founding Sol-Gel, Dr. Seri-Levy established the computer-aided drug design…

De56992926ab5dfcf2a1a119ad2d06d0_3c286c5392adb65fb24e46383a1187a1_120_120
Sol-Gel Technologies Ltd.
Gilad Mamlok, Chief Financial Officer / Sol-Gel Technologies Ltd.
Mr. Gilad Mamlok has served as Sol-Gel's chief financial officer since February 2017. From August 2015 to January 2017, Mr. Mamlok served as the chief financial officer for Medigus Ltd., a medical device company dual listed on Nasdaq and the Tel Aviv…

10b768ed45c279c3e18de475b1c0ea33_2bea23dd5b708058e0702cc31439617e_120_120
Sol-Gel Technologies Ltd.
John Vieira, US Head of Commercialization / Sol-Gel Technologies Ltd.
Mr. John Vieira has served as our U.S. head of commercialization since January 2019. Prior to joining Sol-Gel, Mr. Vieira served in U.S. and Global Marketing roles at Leo Pharmaceuticals. Prior to Leo Pharmaceuticals, Mr. Vieira was Executive…

E4e4d1e2ec69fc571f0841eca8f97eba_b290a8571635167dbc1513722678d3d6_120_120
BMO Capital Markets
Gary Nachman, Managing Director, Specialty Pharmaceuticals Research Analyst / BMO Capital Markets
Gary is a senior research analyst in BMO Capital Markets Equity Research covering specialty pharmaceuticals. Prior to joining BMO in February 2016, Gary was most recently a senior research analyst at Goldman Sachs covering specialty pharma. With a…

TBA
Joseph Pant­gi­nis from H.C. Wain­wright to dis­cuss Lin­eage
Webcast
D6e9e3e9adbcb505f8c71a5f023008a2_3742d14743ac09839fb1271fcc03a121_120_120
Lineage Cell Therapeutics Inc.
Brian Culley, CEO/Interim CFO / Lineage Cell Therapeutics Inc.
Mr. Culley joined Lineage Cell Therapeutics as CEO in September 2018. Prior to joining Lineage Cell Therapeutics, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he…

1d279817ee262af10c49825b897347e8_0d6983702e1c322864ddd67228f9b995_120_120
Lineage Cell Therapeutics Inc.
Brandi Roberts, Chief Financial Officer / Lineage Cell Therapeutics Inc.
Ms. Roberts joined Lineage as Chief Financial Officer in January 2019. Prior to joining Lineage, Ms. Roberts served from August 2017 to January 2019 as Chief Financial Officer at REVA Medical, Inc. Ms. Roberts previously served as Chief Financial…

C703813dbd552a3a01225f9290e7cafe_9e397c3d02e945c1ab8e06955b43c924_120_120
H.C. Wainwright & Co., LLC
Joseph Pantginis, Ph.D., Director of Research, Managing Director / H.C. Wainwright & Co., LLC
Dr. Pantginis has over 20 years of sell-side experience covering biotechnology companies, having spent most of those years at ROTH Capital Partners and Canaccord Adams. Prior to his sell-side career, he worked at Regeneron Pharmaceuticals, where he…

TBA
Sou­mit Roy from Jones Trad­ing to dis­cuss Ber­Gen­Bio
Webcast
C2170edb0a428fa3e5e3e3600c30dd13_9ba83e28af3dbf68b8c7529860306644_120_120
BerGenBio
Richard Godfrey, CEO / BerGenBio
Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008. He has more than 25 years’ industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of…

2e451b0432cbd236dbdebed3cf7c1382_f5cb4356d644ae6c36f6f356595c7cfa_120_120
Jones Trading
Soumit Roy, PhD, Equity Research Analyst / Jones Trading
Soumit Roy is a Healthcare Equity Research analyst with focus on disruptive technology, primarily oncology companies developing T cell therapy, targeted medicines and next generation of immuno-oncology. Prior to joining JonesTrading in 2018, Dr. Roy…

TBA
Biren Amin from Jef­feries to dis­cuss Zen­talis
Webcast
226b85e5d44e9800211ecfedb3209ba8_11848a04890cba5253bffe857a31e6ee_120_120
Zentalis
Anthony Sun, CEO / Zentalis
Anthony has played an active role across the life science industry since 2002 and currently serves as Chief Executive Officer for Zentalis Pharmaceuticals. From 2002 until 2015, he was at Aisling Capital and Perseus-Soros Biopharmaceutical Fund…

7b96017db698b7832f9e2958eb064346_bb2fdc5c6d2f14c0793a06bcbfe30fc1_120_120
Zentalis
Melissa Epperly, CFO / Zentalis
Melissa is Chief Financial Officer at Zentalis Pharmaceuticals. She brings extensive experience as a senior financial executive in the life sciences industry. She most recently served as CFO at PsiOxus Therapeutics, a clinical-stage gene therapy…

8359aeafa63fbcf0590b18664cfd9f8d_68251e843959c39654be8519d0d20ab2_120_120
Jefferies LLC
Biren Amin / Jefferies LLC
Amin is a senior research analyst at Jefferies, LLC. He is assisted by Hugo Ong and joined the firm in June 2011. Previously, Amin was an analyst at WJB Capital Group (February 2010-June 2011). Prior to that, he was into biotech equity research at…

TBA
Yatin Sune­ja to dis­cuss Ex­i­cure
Webcast
A6304bba826bb4b3f4911079288c032d_23826be9659b9e80a57a25e889c5f599_120_120
Exicure
David Giljohann, PhD, COO / Exicure
Dr. Giljohann has served as our CEO since November 2013 and been on our board of directors since March 2014. From July 2012 to October 2013, Dr. Giljohann was our Chief Operating Officer. From 2011 until June 2012, Dr. Giljohann served as our…

68c2385195b85e6a81bd0e6759092b17_966802f6be6371606514aac429350033_120_120
Exicure
David Snyder, CFO / Exicure
Mr. Snyder joined our executive leadership team as Chief Financial Officer in July 2014. Prior to joining the Company, Mr. Snyder was Executive Vice President and Chief Financial Officer of Cellular Dynamics International, Inc. where he was…

8450ab20ceb17b3470e1082bd36c319f_025ff83fe40aad186bbb81735057a058_120_120
Guggenheim Securities, LLC
Yatin Suneja, Senior Biotechnology Analyst / Guggenheim Securities, LLC
Now at Guggenheim, Yatin Suneja served at STRH as a director providing Biotech research coverage. Suneja was most recently at Cowen and Company, where he spent the last four years covering Biotech stocks. Prior to Cowen, he was a key member of the…
Export to Excel